Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...

The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...

The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) ...

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

Sanofi SA (EPA: SASY) announced Friday that its drug Sarclisa has received approval in the European Union for the treatment of transplant-eligible newly diagnosed ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market.

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development ...

Vertiv (NYSE:VRT) has agreed to acquire the Great Lakes Data Racks & Cabinets family of companies for $200 million. Vicebio, ...

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...